Contributing to the Transformational Change Across Healthcare on the African Continent
The World Health Organization (WHO) and the International Finance Corporation (IFC) issued a joint declaration on the urgent unmet medical need for disease prevention and healthcare product access across developing countries. MiGenTra contributes by enhancing accessibility to critical and lifesaving medicines at affordable prices for Egypt, the Middle East and Africa (MEA) while simultaneously strengthening manufacturing capacities in the region. The company is ideally positioned to transform the lives of millions in urgent medical need.
Development and Manufacturing of Therapeutics and Vaccines to Ensure Affordable Access to Essential Medicines
MiGenTra combines the extensive scientific and manufacturing expertise from both parent companies, ProBioGen and Minapharm Pharmaceuticals, for product development and commercialization in the field of biosimilars, cell and gene therapies (CGT), and vaccines, capitalizing on the strong development capabilities and the excellent market position in the MEA region.
Relying on a strong foothold in the region and a proven track record to develop and locally manufacture groundbreaking treatments and exploit unmet emerging market opportunities
Cell and Gene Therapies (CGT)
Providing first class knowledge and expertise in cell line and process development to address the unmet medical needs of underrepresented patient groups
Contract development and manufacturing of viral vectors at local facilities, with EMA/WHO GMP compliance certification in progress
Combining Unique Strengths and Capabilities to Bring Critical Medicines and Services to Market
On the pulse of time, MiGenTra establishes forward-looking and disruptive go-to-market models that cater to the urgent medical needs of patients in developing countries and enable the objectives of the WHO and IFC.
MiGenTra fuses the distinct strengths and capabilities of its two founding companies, ProBioGen (Berlin, Germany) and Minapharm Pharmaceuticals (Cairo, Egypt), to bring a unique and comprehensive offer to market. ProBioGen has garnered international recognition for its team of scientists and their unparalleled knowledge in the advancement of cutting-edge technologies and development and manufacture of active ingredients and vaccines. With its successful track record with biosimilars and a strong foothold in the region, Minapharm is firmly positioned ahead of the local competition to:
Evaluate large untapped market opportunities for healthcare products already in development
Build strong collaborations with biopharmaceutical partners for commercialization and branding
Select new molecules as well as early in-house development of wave 3 molecules